Technical Analysis for RLMD - Relmada Therapeutics Inc

Grade Last Price % Change Price Change
grade A 2.47 0.82% 0.0200
RLMD closed up 0.82 percent on Friday, August 23, 2019, on 20 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RLMD trend table...

Date Alert Name Type % Chg
BB Squeeze Ended Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish 0.82%
Bollinger Band Squeeze Range Contraction 0.82%
Stochastic Reached Overbought Strength 0.82%
BB Squeeze + Upper Band Touch Range Contraction 0.82%
Above Upper BB Strength 0.82%

Older signals for RLMD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.
Biotechnology RTT Euphoriants Drugs Pain Psychoactive Drugs Diseases Depression Opioids Opioid Analgesic Drug Products Buprenorphine Neuropathic Pain Chemical Entities Methadone
Is RLMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.418
52 Week Low 0.8
Average Volume 33,642
200-Day Moving Average 1.7194
50-Day Moving Average 2.0892
20-Day Moving Average 2.2323
10-Day Moving Average 2.2905
Average True Range 0.126
ADX 27.62
+DI 31.5971
-DI 10.8989
Chandelier Exit (Long, 3 ATRs ) 2.092
Chandelier Exit (Short, 3 ATRs ) 2.248
Upper Bollinger Band 2.4207
Lower Bollinger Band 2.0439
Percent B (%b) 1.13
BandWidth 16.879452
MACD Line 0.0904
MACD Signal Line 0.0663
MACD Histogram 0.0241
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.6500
Resistance 3 (R3) 2.6300 2.5500 2.6200
Resistance 2 (R2) 2.5500 2.5042 2.5600 2.6100
Resistance 1 (R1) 2.5100 2.4758 2.5300 2.5300 2.6000
Pivot Point 2.4300 2.4300 2.4400 2.4400 2.4300
Support 1 (S1) 2.3900 2.3842 2.4100 2.4100 2.3400
Support 2 (S2) 2.3100 2.3558 2.3200 2.3300
Support 3 (S3) 2.2700 2.3100 2.3200
Support 4 (S4) 2.2900